Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection

Therapeutic Drug Monitoring

Volumn 38, Issue 5, 2016, Pages 640-645

  Badri, Prajakta S ^a   Parikh, Apurvasena ^a   Coakley, Eoin P ^b,d   Ding, Bifeng ^c   Awni, Walid M ^a   Dutta, Sandeep ^a   Menon, Rajeev M ^a  

^a Department of Clinical Pharmacokinetics and Pharmacodynamics ^*  (United States)

^b Infectious Disease Development   (United States)

^c ABBVIE INC   (United States)

^d ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

calcineurin inhibitors; dasabuvir; liver transplant; ombitasvir; paritaprevir

Indexed keywords

CREATININE; CYCLOSPORIN A; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; TACROLIMUS; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MINIMUM PLASMA CONCENTRATION; ORAL CLEARANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PREDICTIVE VALUE; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIMULATION; TREATMENT DURATION; VOLUME OF DISTRIBUTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; FEMALE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; CYCLOSPORINE; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RITONAVIR; SULFONAMIDES; TACROLIMUS; URACIL; YOUNG ADULT;

EID: 84975142613     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000315     Document Type: Article

References (25)

1. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147: 359-365.
2. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 1983-1992.
3. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1594-1603.
4. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1604-1614.
5. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370: 1973-1982.
6. Dall'Agata M, Gramenzi A, Biselli M, et al. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? World J Gastroenterol. 2014; 20: 9253-9260.
7. Jimenez-Perez M, Gonzalez-Grande R, Rando-Munoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol. 2014; 20: 16409-16417.
8. Wawrzynowicz-Syczewska M, Zeair S, Andruszkiewicz A, et al. Impact of antiviral treatment on survival in HCV-positive liver recipients. Ann Transplant. 2014; 19: 367-372.
9. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014; 371: 2375-2382.
10. Barbarino JM, Staatz CE, Venkataramanan R, et al. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013; 23: 563-585.
11. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009; 158: 693-705.
12. Badri PS, King JR, Polepally AR, et al. Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet. 2016; 55: 275-295.
13. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015; 15: 1313-1322.
14. Mantry PS, Brown RS, Enejosa J, et al. Ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin for HCV patients with post-transplant recurrence. Hepatology. 2015; 62(suppl): 742A.
15. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003; 9: 1159-1165.
16. Vukotic R, Morelli MC, Pinna AD, et al. Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients. Aliment Pharmacol Ther. 2014; 40: 405.
17. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ ritonavir in liver-transplanted HIV-infected patients. Liver Transpl. 2004; 10: 939-944.
18. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant. 2003; 18(suppl 1): i12-i15.
19. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003; 9: 954-960.
20. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60: 78-86.
21. Kwo PY, Ghabril M, Lacerda MA, et al. Telaprevir with peginterferon/ ribavirin for retreatment of null responders with advanced fibrosis postorthotopic liver transplant. Clin Transplant. 2014; 28: 722-727.
22. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003; 74: 245-254.
23. Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2004; 42: 701-718.
24. Viekira Pak (US prescribing information). North Chicago, IL: AbbVie Inc; 2016.
25. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transpl. 2009; 9: 2505-2513.